Estrella Immunopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended December 31, 2025 | For the Six Months Ended December 31, 2024 | |
|---|---|---|
| (Short Year) | ||
| Operating expenses | ||
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | $10,248,545 | $2,858,566 |
| General and administrative (including $265,448 for the year ended December 31, 2025 and $103,667 for the six months ended December 31, 2024, from related parties) | 2,814,129 | 1,568,398 |
| Total operating expenses | 13,062,674 | 4,426,964 |
| Loss from Operations | (13,062,674) | (4,426,964) |
| Loss before income taxes | (13,062,674) | (4,426,964) |
| Income tax provision | (838) | (63) |
| Net loss | $(13,063,512) | $(4,427,027) |
| Net loss applicable to common stock per share, basic and diluted | $(0.35) | $(0.12) |
| Weighted average common stock outstanding, basic and diluted | 36,820,810 | 36,515,688 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.